Advance your practice with new education on oral SERD eligibility in EBC. Gain expert insight into landmark trials, learn exactly who qualifies for novel therapies, and elevate the care you deliver and the outcomes you can achieve for the patients you treat every day. Vyc

📌 #ASH26 is BACK! 🚀 Ready to bring bispecific antibodies into R/R MM care? Review key🔑 trial data, navigate barriers to implementation, and explore strategies to manage AEs while expanding access. 🧩 Build individualized care plans with confidence. Save your spot! g

🔮 Is your patient’s SM truly under control? Dive into emerging evidence across the spectrum of systemic mastocytosis and 🧬 sharpen your ability to recognize when advanced treatment may be needed. 📣 Bring the latest evidence into practice! mdsc.pe/4yhO28u #ASH26

Episodic therapy, not suppression, is often the real risk factor for refractory HSV.

Hear Dr. Anna Wald and Dr. Princy Kumar review why clinical resistance happens and how care is evolving.

Catch the replay ➡️ mdsc.pe/4A89e1B

#InfectiousDisease #CME #MedEd

Discover our new curriculum featuring Dr Aditya Bardia, who shares expert perspectives on emerging oral SERD strategies and their potential role in advancing care for patients with early breast cancer.

mdsc.pe/4z5AwF8

⏳ The countdown to #ASH26 begins! Save this post now and start planning your must-attend sessions! 📌 From diagnosis to personalized treatment, every decision matters in AL amyloidosis. 🔎 Gain practical insights for interpreting clinical findings 👇 mdsc.pe/4x5jqGX

🩸 When rare hematologic conditions challenge the usual playbook, be ready. Decode atypical presentations, 🧬 explore novel targeted therapies & sharpen diagnostic and treatment strategies 🎯 Build confidence for complex cases—secure your spot today! mdsc.pe/46oDsAC

#ASH26

🩸 From molecular profiling to treatment selection, MDS care continues to evolve!

Explore emerging clinical evidence and strategies for managing treatment complexities across the disease continuum.

🎯 Advance your expertise! mdsc.pe/47pCQv9

🔬 How can you optimize care for patients with newly diagnosed multiple myeloma ?

Explore clinical evidence for transplant-eligible and ineligible patients, personalized treatment strategies, and the importance of collaborative care.

💡 Strengthen your clinical is educational activity! mdsc.pe/3U0ktts #ASH26

🔍 MDS treatment decisions are becoming increasingly precise. Discover how cytogenetic and molecular characteristics can guide care, examine trial data 🧪 across the disease continuum & strengthen team-based management of treatment complexities. ⚡ Turn evolving evidence into actio/P2a2mnCMSW #ASH26

🧬 Choosing the right TKI in CML starts with the right data. Explore first-line selection, navigate resistance & translate mutational analysis into therapeutic decisions with coordinated team-based care. 🎯 Sharpen your CML strategy—register today! mdsc.pe/4zRXX6p #ASH26

💡 How can clinicians translate advances in immuno-oncology into better treatment decisions? Explore antigen-directed therapies, biomarker-driven selection & practical strategies for individualized cancer care. 🔬

📢 Stay ahead of emerging evidence—explore this educational actit.co/fdZPyBZVhl

🦟 Stay current on dengue prevention! Explore the latest data, strengthen vaccine 💉recommendations, and gain confidence addressing patient questions and concerns about dengue vaccination. 🌎 Click here now: mdsc.pe/4ARfGLF

Spotlight on NTRK Fusions: Clinical Care Insights Across Lung and Thyroid Cancer x.com/i/broadcasts/2…

Starting in 1 HOUR ➡️ mdsc.pe/4k9208O

Gain expert insights on NTRK fusions in lung and thyroid cancer. Join LIVE!

🗓️ Today
⏰ 12:00pm EST

#Oncology #NTRKFusions #MedEd

🧬 MASH care is moving beyond liver-only thinking. Explore the MASLD-to-MASH spectrum, cardiometabolic risk, emerging therapies, noninvasive risk assessment, and phenotype-driven treatment strategies. 📊 Advance your approach—register today! mdsc.pe/3U4CNS7

PBC treatment checkpoint: 🛑➡️🟢
First-line response falling short? Explore when to advance therapy, how to select second-line options, and 🧬 how to build management around what matters to the patient. 💬 Ready for the next step? Join us! mdsc.pe/4iRKdlN

Oral SERDs bring new possibilities for patients with early breast cancer. By integrating emerging evidence with clinical experience, we can drive meaningful progress in treatment strategies.

mdsc.pe/4z5AwF8

🧪 Systemic mastocytosis care is evolving across the disease spectrum. Explore recent clinical trial data, identify patients who may benefit from advanced treatment & ✨ evaluate whether disease control is truly adequate. 🧭 Stay ahead of SM care—register today! httpH26

🧬 What's new in sickle cell disease (SCD) care? Explore gene therapies, emerging PK activators, and personalized treatment strategies.

🔍 Expand your clinical knowledge—join this educational activity! mdsc.pe/4zpr7Zo #ASH26